Literature DB >> 16170394

MCL-1 (myosin light chains-1) in differential diagnosis of dyspnea.

David Stejskal1, Borek Lacnák, Katerina Andelová, Marcela Skvarilová, Josef Bartek.   

Abstract

Myosin light chains-1 (MLC-1) have been recently associated with the markers of heart function (NYHA, LVEF, NT-proBNP). Verification of the relationship between markers of heart function (New York Heart Association classification (NYHA), left ventricle ejection fraction determination (LVEF), N terminal prohormone of natriuretic peptide B type BNP (NT-proBNP) and concentrations of myosin light chains-1 (MLC-1) was assessed. Patients examined for dyspnea without signs of acute coronary syndrome. All patients underwent echocardiography (calculation of left ventricle ejection fraction--LVEF) and in the serum of all subjects NT-proBNP (ELEIA) and MLC-1 (ELISA) were determined. In the 38 patients (21 men, 17 women), mean age of 58 years (+/-12 years as 1 SD), a significant negative correlation was found between NT-proBNP and LVEF (r = - 0.47; p = 0.02, Spearman). The median levels of NT pro-BNP were closely associated with NYHA classification (type II--584 ng/l, type III--2792 ng/l, type IV--6400 ng/l; p < 0.05). Individuals with clinical NYHA IV differed significantly in median MLC-1 concentrations from persons with clinical NYHA classification II and III (type II--5.7 ng/l, type III--8.9 ng/l, type IV--17 ng/l; p < 0.05). A significant negative correlation between MLC-1 and LVEF (-0.35; p < 0.03) and significant positive correlations between MLC-1 and NT-proBNP (0.42; p < 0.012) were found. In conclusion MLC-1 cannot be used as a diagnostic marker in differential diagnosis of dyspnea.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16170394

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN: 1213-8118            Impact factor:   1.245


  3 in total

1.  An Initial Evaluation of Human Plasma cMLC-1: A Potential Protein Biomarker for Trastuzumab-Induced Cardiotoxicity, Breast Cancer Screening and Progression.

Authors:  Ling Yu; Read Allen; Lin Jia; Ting Sun; Steven J Isakoff; Marielle Scherrer-Crosbie; Allison M Kehlmann; Hui Zheng; Amy Ly; Charlotte S Walmsley; Katherine Hesler; Ava N Varasteh; Christopher J Pinto; Daniel E McLoughlin; Wenjin Wu; Xinhui Wang
Journal:  Front Oncol       Date:  2022-05-03       Impact factor: 5.738

2.  Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice.

Authors:  M Khair ElZarrad; Partha Mukhopadhyay; Nishant Mohan; Enkui Hao; Milos Dokmanovic; Dianne S Hirsch; Yi Shen; Pal Pacher; Wen Jin Wu
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

3.  Biomarker panel for early screening of trastuzumab -induced cardiotoxicity among breast cancer patients in west virginia.

Authors:  Sneha S Pillai; Duane G Pereira; Gloria Bonsu; Hibba Chaudhry; Nitin Puri; Hari Vishal Lakhani; Maria Tria Tirona; Komal Sodhi; Ellen Thompson
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.